Verici Dx plc
("Verici Dx" or the "Company")
Result of AGM and voting results
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:
| | In Favour | Against | Withheld | ||
| Resolution | Votes | % | Votes | % | Votes |
| 1 | 62,212,695 | 100 | 0 | 0 | 0 |
| 2 | 62,212,118 | 100 | 577 | 0 | 0 |
| 3 | 62,212,545 | 100 | 0 | 0 | 150 |
| 4 | 52,879,826 | 85 | 9,332,869 | 15 | 0 |
| 5 | 51,490,878 | 83 | 10,720,067 | 17 | 1,750 |
Enquiries:
| Verici Dx | |
| Sara Barrington, CEO | Via Walbrook PR |
| Julian Baines, Chairman |
|
| | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell / Kailey Aliyar / Rachel Hayes | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or vericidx@walbrookpr.com |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
